Clinical Trial Update: Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone [Phase 1]

View source ↗

Summary

Phase 1 safety update on LBH589 (panobinostat) alone and with intravenous docetaxel and prednisone in men with hormone-refractory prostate cancer; the trial sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• LBH589 (panobinostat)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hormone Refractory Prostate Cancer Disease | Phase 1 | Status: TERMINATED